My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
COMPLIANCE INFO_2004-2020
EnvironmentalHealth
>
EHD Program Facility Records by Street Name
>
Y
>
YOSEMITE
>
1777
>
4500 - Medical Waste Program
>
PR0450109
>
COMPLIANCE INFO_2004-2020
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
11/8/2024 3:08:48 PM
Creation date
7/3/2020 10:18:19 AM
Metadata
Fields
Template:
EHD - Public
ProgramCode
4500 - Medical Waste Program
File Section
COMPLIANCE INFO
FileName_PostFix
2004-2020
RECORD_ID
PR0450109
PE
4522 - ACUTE CARE FACILITY
FACILITY_ID
FA0003978
FACILITY_NAME
KAISER FOUNDATION - MANTECA
STREET_NUMBER
1777
Direction
W
STREET_NAME
YOSEMITE
STREET_TYPE
AVE
City
MANTECA
Zip
95337
APN
20018034
CURRENT_STATUS
Active, billable
QC Status
Approved
Scanner
SJGOV\cfield
Supplemental fields
FilePath
\MIGRATIONS\MW\MW_4522_PR0450109_1777 W YOSEMITE_.tif
Site Address
1777 W YOSEMITE AVE MANTECA 95337
Tags
EHD - Public
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
195
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
! • <br /> State of California-Heaith and Welfare Agency Department of Health Services <br /> Page 4 of 5 pages <br /> RADIOACTIVE MATERIAL LICENSE License Number. 5790-39 <br /> Supplementary Sheet Amendment Number: 9 <br /> 23. The licensee shall elute generators and process radioactive material with reagent kits in accordance with <br /> instructions furnished by the manufacturer on the label attached to or in the leaflet or brochure that <br /> accompanies the generator or reagent kit. <br /> 24. Technetium 99m labelled pharmaceuticals prepared by the licensee by aseptic addition of pertechnetate to <br /> sterile, pyrogen free reagents may be administered to humans provided the radioassay of the final product is <br /> determined with an overall error not exceeding ten percent. When the pharmaceutical is prepared from reagents <br /> procured in the form of approved kits, the licensee must strictly follow all instructions and recommendations <br /> contained in the package insert information;otherwise the pharmaceutical must be prepared and compounded <br /> from a prescription in accordance with the regulations of the California Board of Pharmacy. <br /> 25. The licensee is authorized to hold radioactive materials with a physical half life of less than 65 days for decay <br /> in storage before disposal in ordinary trash provided: <br /> (a) Radioactive waste to be disposed of in this manner shall be held for decay in storage for no less than 10 <br /> half lives. <br /> (b) Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity <br /> cannot be distinguished from background. All radiation labels shall be removed or obliterated. <br /> 26. Equipment for radiometric assay of pharmaceuticals, body fluids, excreta, or in-vitro assay samples shall be <br /> calibrated to ensure reliability of data obtained. The stability of the equipment shall be checked at least once <br /> each day of use, using appropriate standards. <br /> 27. Nuclear medicine technology procedures shall be performed by nuclear medicine technologists pursuant to the <br /> Title 17, California Code of Regulations, Subchapter 4.6. Such procedures shall be performed under the <br /> supervision of individuals listed as authorized users on this license who meet the criteria specified in Section <br /> 30510. Certificates or special permits issued pursuant to Subchapter 4.6 shall be prominently displayed at the <br /> facility(ies)authorized on this license. <br /> 28. Treatment and management of patients receiving therapeutic quantities of unsealed radioactive materials shall <br /> be in accordance with guidance contained in Chapter 4, "Release from Hospital of Patients Containing <br /> Radioactive Material" National Council on Radiation Protection and Measurements(NCRP) Report No. 37, <br /> "Precautions in the Management of Patients Who Have Received Therapeutic Amounts of Radionuclides" <br /> (NCRP Publications, P. O. Box 30175, Washington, D. C., 20014). <br /> 29. This license does not authorize distribution to persons licensed pursuant to Title 17, California Code of <br /> Regulations, Section 30195 (a) and (b) or equivalent provisions of the U.S. Nuclear Regulatory Commission <br /> or Agreement States. <br /> 30. This license does not authorize commercial distribution of radioactive material. <br /> 31. Production or processing of radiopharmaceuticals for the purpose of distribution to other licensees is not <br /> authorized by this license. <br />
The URL can be used to link to this page
Your browser does not support the video tag.